Thea Kristin Våtsveen
- Researcher; PhD
Shared position with Blood and Lymphoproliferative Diseases group, led by Ludvig Munthe
Publications 2024
Cell surface marker heterogeneity in human myeloma cell lines for modeling of disease and therapy
Sci Rep, 14 (1), 28805
DOI 10.1038/s41598-024-80263-y, PubMed 39567630
Publications 2022
Mechanism of CD79A and CD79B Support for IgM+ B Cell Fitness through B Cell Receptor Surface Expression
J Immunol, 209 (10), 2042-2053
DOI 10.4049/jimmunol.2200144, PubMed 36426942
Publications 2021
Karonudib has potent anti-tumor effects in preclinical models of B-cell lymphoma
Sci Rep, 11 (1), 6317
DOI 10.1038/s41598-021-85613-8, PubMed 33737576
MTH1 Inhibitor TH1579 Induces Oxidative DNA Damage and Mitotic Arrest in Acute Myeloid Leukemia
Cancer Res, 81 (22), 5733-5744
DOI 10.1158/0008-5472.CAN-21-0061, PubMed 34593524
Publications 2018
Artesunate shows potent anti-tumor activity in B-cell lymphoma
J Hematol Oncol, 11 (1), 23
DOI 10.1186/s13045-018-0561-0, PubMed 29458389
Publications 2016
Phosphatase of regenerating liver 3 (PRL-3) is overexpressed in human prostate cancer tissue and promotes growth and migration
J Transl Med, 14, 71
DOI 10.1186/s12967-016-0830-z, PubMed 26975394
VOLIN and KJON-Two novel hyperdiploid myeloma cell lines
Genes Chromosomes Cancer, 55 (11), 890-901
DOI 10.1002/gcc.22388, PubMed 27311012
Erythropoietin (EPO)-receptor signaling induces cell death of primary myeloma cells in vitro
J Hematol Oncol, 9 (1), 75
DOI 10.1186/s13045-016-0306-x, PubMed 27581518
Publications 2015
Proteasome inhibitors and IMiDs can overcome some high-risk cytogenetics in multiple myeloma but not gain 1q21
Eur J Haematol, 96 (1), 46-54
DOI 10.1111/ejh.12546, PubMed 25779478
Allelic mutations in noncoding genomic sequences construct novel transcription factor binding sites that promote gene overexpression
Genes Chromosomes Cancer, 54 (11), 692-701
DOI 10.1002/gcc.22280, PubMed 26220195
Publications 2014
Bone morphogenetic protein-9 suppresses growth of myeloma cells by signaling through ALK2 but is inhibited by endoglin
Blood Cancer J, 4 (3), e196
DOI 10.1038/bcj.2014.16, PubMed 24658374
Identification of the source of elevated hepatocyte growth factor levels in multiple myeloma patients
Biomark Res, 2 (1), 8
DOI 10.1186/2050-7771-2-8, PubMed 24716444
Publications 2013
Targeting proliferating cell nuclear antigen and its protein interactions induces apoptosis in multiple myeloma cells
PLoS One, 8 (7), e70430
DOI 10.1371/journal.pone.0070430, PubMed 23936203
Publications 2012
Addiction to c-MYC in multiple myeloma
Blood, 120 (12), 2450-3
DOI 10.1182/blood-2011-08-371567, PubMed 22806891
Publications 2011
Bone morphogenetic proteins induce apoptosis in multiple myeloma cells by Smad-dependent repression of MYC
Leukemia, 26 (5), 1073-80
DOI 10.1038/leu.2011.263, PubMed 21941367
Publications 2009
High expression of BCL3 in human myeloma cells is associated with increased proliferation and inferior prognosis
Eur J Haematol, 82 (5), 354-63
DOI 10.1111/j.1600-0609.2009.01225.x, PubMed 19191868
c-Met signaling promotes IL-6-induced myeloma cell proliferation
Eur J Haematol, 82 (4), 277-87
DOI 10.1111/j.1600-0609.2009.01212.x, PubMed 19187270
FGFR3 is expressed and is important for survival in INA-6, a human myeloma cell line without a t(4;14)
Eur J Haematol, 83 (5), 471-6
DOI 10.1111/j.1600-0609.2009.01312.x, PubMed 19594619
OH-2, a hyperdiploid myeloma cell line without an IGH translocation, has a complex translocation juxtaposing MYC near MAFB and the IGK locus
Leuk Res, 33 (12), 1670-7
DOI 10.1016/j.leukres.2009.03.001, PubMed 19395026
Publications 2007
Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells
Blood, 111 (2), 806-15
DOI 10.1182/blood-2007-07-101139, PubMed 17934070